C0037459||ESMO
C0376636||Management
C0027498||nausea and vomiting
C0877373||advanced cancer
C0282443||review
C0023866||literature
C0376636||management
C0027498||nausea and vomiting
C0027498||N & V
C0877373||advanced cancer
C0376636||management
C1955832||systematic reviews
C0003297||antiemetic drug
C1955832||systematic review
C0003297||antiemetics
C0877373||advanced cancer
C4255373||Agreement
C0680022||panel members
C0003297||antiemetic
C0008976||trials
C0008976||trials
C0085973||case studies
C0393009||level of evidence
C0947630||studies
C1254351||drug
C0376636||managing
C0027498||N & V
C0877373||advanced cancer
C0025853||metoclopramide
C0018546||haloperidol
C0025678||levomepromazine
C0171023||olanzapine
C0021843||bowel obstruction
C0028833||octreotide
C0003297||antiemetic
C0018546||haloperidol
C0028833||octreotide
C0242896||anticholinergic antisecretory agent
C0242402||opioid
C0027498||N & V
C0162791||guidelines
C0871685||clinicians
C0376636||manage
C1457887||symptoms
C0027498||N & V
C0877373||advanced cancer